PlantForm Corporation awarded Best Specialty Protein Drug Biopharmaceutical Company 2019
GUELPH, Ont., October 2, 2019—PlantForm Corporation has been awarded Best Speciality Protein Drug Biopharmaceutical Company 2019 in Global Health & Pharma’s 2019 Healthcare and Pharmaceutical Awards.
“PlantForm is pleased to be recognized for our exceptionally versatile vivoXPRESS® biopharmaceutical manufacturing platform for speciality antibody drugs, protein drugs and vaccines,” said Dr. Don Stewart, PlantForm President and CEO.
“We are using the vivoXPRESS® platform to develop a wide range of products, from biosimilar programs with partners in Brazil and South Africa to medical countermeasures for biosecurity and other threats through our subsidiary AntoXa Corporation.”
The vivoXPRESS® manufacturing platform is also available for licensing opportunities. It is being used by clients from around the world for a wide range of targets through collaboration and research agreements and programs.
The growing portfolio of countermeasures, for example, includes a best-in-class, highly potent antibody for ricin exposure developed by AntoXa Corporation in partnership with the Government of Canada.
About PlantForm Corporation (www.plantformcorp.com)
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty antibody and protein drugs using the company’s proprietary vivoXPRESS® platform
. The plant-based vivo
system makes it easier, faster and less expensive to produce approved biologic drugs for novel indications and new markets. The company’s pipeline includes trastuzumab for a novel indication in nerve regeneration, a biosimilar version of Lucentis® and other niche indication drugs. Learn more.
For more information, please contact:
For more on vivoXPRESS® licensing opportunities for biopharmaceutical research and development, contact:
Chief Operating Officer, PlantForm Corp.
Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook: